420 related articles for article (PubMed ID: 16929560)
21. Evaluation of carboplatin pharmacokinetics in pediatric oncology by means of inductively coupled plasma mass spectrometry.
Clerico A; Cappelli C; Ragni G; Caroli S; De Ioris MA; Sordi A; Petrucci F; Bocca B; Alimonti A
Ann Ist Super Sanita; 2006; 42(4):461-8. PubMed ID: 17361071
[TBL] [Abstract][Full Text] [Related]
22. Presence of cancerostatic platinum compounds in hospital wastewater and possible elimination by adsorption to activated sludge.
Lenz K; Hann S; Koellensperger G; Stefanka Z; Stingeder G; Weissenbacher N; Mahnik SN; Fuerhacker M
Sci Total Environ; 2005 Jun; 345(1-3):141-52. PubMed ID: 15919535
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of (glycolate-0,0')-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin.
Sasaki Y; Tamura T; Eguchi K; Shinkai T; Fujiwara Y; Fukuda M; Ohe Y; Bungo M; Horichi N; Niimi S
Cancer Chemother Pharmacol; 1989; 23(4):243-6. PubMed ID: 2647312
[TBL] [Abstract][Full Text] [Related]
24. A full validated hydrophilic interaction liquid chromatography-tandem mass spectrometric method for the quantification of oxaliplatin in human plasma ultrafiltrates.
Ito H; Yamaguchi H; Fujikawa A; Tanaka N; Furugen A; Miyamori K; Takahashi N; Ogura J; Kobayashi M; Yamada T; Mano N; Iseki K
J Pharm Biomed Anal; 2012 Dec; 71():99-103. PubMed ID: 22954448
[TBL] [Abstract][Full Text] [Related]
25. Determination of platinum originated from antitumoral drugs in human urine by atomic absorption spectrometric methods.
da Costa AC; Vieira MA; Luna AS; de Campos RC
Talanta; 2010 Oct; 82(5):1647-53. PubMed ID: 20875558
[TBL] [Abstract][Full Text] [Related]
26. Determination of platinum originating from carboplatin in human urine and canine excretion products by inductively coupled plasma mass spectrometry.
Janssens T; Brouwers EE; de Vos JP; Schellens JH; Beijnen JH
J Anal Toxicol; 2011 Apr; 35(3):153-61. PubMed ID: 21439151
[TBL] [Abstract][Full Text] [Related]
27. Specific determination of intact cisplatin and monohydrated cisplatin in human plasma and culture medium ultrafiltrates using HPLC on-line with inductively coupled plasma mass spectrometry.
Bell DN; Liu JJ; Tingle MD; McKeage MJ
J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Jun; 837(1-2):29-34. PubMed ID: 16697278
[TBL] [Abstract][Full Text] [Related]
28. Comparative pharmacokinetics of cisplatin and three analogues in mice and humans.
van Hennik MB; van der Vijgh WJ; Klein I; Elferink F; Vermorken JB; Winograd B; Pinedo HM
Cancer Res; 1987 Dec; 47(23):6297-301. PubMed ID: 3315183
[TBL] [Abstract][Full Text] [Related]
29. Early biotransformations of oxaliplatin after its intravenous administration to cancer patients.
Allain P; Heudi O; Cailleux A; Le Bouil A; Larra F; Boisdron-Celle M; Gamelin E
Drug Metab Dispos; 2000 Nov; 28(11):1379-84. PubMed ID: 11038167
[TBL] [Abstract][Full Text] [Related]
30. Comparative protein binding, stability and degradation of satraplatin, JM118 and cisplatin in human plasma in vitro.
Bell DN; Liu JJ; Tingle MD; Rattel B; Meyer TU; McKeage MJ
Clin Exp Pharmacol Physiol; 2008 Dec; 35(12):1440-6. PubMed ID: 18671714
[TBL] [Abstract][Full Text] [Related]
31. A shotgun approach for the identification of platinum-protein complexes.
Moraleja I; Moreno-Gordaliza E; Esteban-Fernández D; Mena ML; Linscheid MW; Gómez-Gómez MM
Anal Bioanal Chem; 2015 Mar; 407(9):2393-403. PubMed ID: 25618759
[TBL] [Abstract][Full Text] [Related]
32. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family).
Yonezawa A; Masuda S; Yokoo S; Katsura T; Inui K
J Pharmacol Exp Ther; 2006 Nov; 319(2):879-86. PubMed ID: 16914559
[TBL] [Abstract][Full Text] [Related]
33. Clinical, analytical and pharmacokinetic aspects in cancer chemotherapy with platinum coordination compounds.
Caroli S; Alimonti A; Petrucci F; La Torre F; Dominici C; Castello MA
Ann Ist Super Sanita; 1989; 25(3):487-97. PubMed ID: 2696394
[TBL] [Abstract][Full Text] [Related]
34. Determination of platinum complexes in clinical samples by a rapid flameless atomic absorption spectrometry assay.
Kloft C; Appelius H; Siegert W; Schunack W; Jaehde U
Ther Drug Monit; 1999 Dec; 21(6):631-7. PubMed ID: 10604824
[TBL] [Abstract][Full Text] [Related]
35. Serial determination of platinum, protein content and free sulfhydryl levels in plasma of patients treated with cisplatin or carboplatin.
Tosetti F; Rocco M; Fulco RA; Chiara S; Bruzzone M; Campora E; Esposito M
Anticancer Res; 1988; 8(3):381-6. PubMed ID: 2839099
[TBL] [Abstract][Full Text] [Related]
36. A validated inductively coupled plasma mass spectrometry (ICP-MS) method for the quantification of total platinum content in plasma, plasma ultrafiltrate, urine and peritoneal fluid.
Lemoine L; Thijssen E; Noben JP; Adriaensens P; Carleer R; Speeten KV
J Pharm Biomed Anal; 2018 Apr; 152():39-46. PubMed ID: 29414017
[TBL] [Abstract][Full Text] [Related]
37. Determination of platinum drug release and liposome stability in human plasma by CE-ICP-MS.
Nguyen TT; Ostergaard J; Stürup S; Gammelgaard B
Int J Pharm; 2013 Jun; 449(1-2):95-102. PubMed ID: 23583709
[TBL] [Abstract][Full Text] [Related]
38. Mass spectrometry study of hemoglobin-oxaliplatin complexes in colorectal cancer patients and potential association with chemotherapeutic responses.
Mandal R; Sawyer MB; Li XF
Rapid Commun Mass Spectrom; 2006; 20(17):2533-8. PubMed ID: 16878345
[TBL] [Abstract][Full Text] [Related]
39. Comparative hydrolysis and plasma protein binding of cis-platin and carboplatin in human plasma in vitro.
Sooriyaarachchi M; Narendran A; Gailer J
Metallomics; 2011 Jan; 3(1):49-55. PubMed ID: 21135941
[TBL] [Abstract][Full Text] [Related]
40. Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system.
Rice JR; Gerberich JL; Nowotnik DP; Howell SB
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2248-54. PubMed ID: 16609041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
